Acute Myeloid Leukemia

Potential new treatments for acute myeloid leukemia

Two separate studies yield key findings for the prevention, diagnosis, treatment and cure for acute myeloid leukemia (AML). AML is a group of heterogeneous diseases with considerable diversity in terms of genetic abnormalities. ...

Nov 25, 2013
popularity1 comments 0

Drug hope for acute myeloid leukemia

A new drug that strips cancer cells of their "immortality" could help to treat patients suffering from one of the most aggressive forms of leukaemia.

Aug 08, 2017
popularity0 comments 0

New biomarkers for acute myeloid leukemia

Mariam Ibáñez, lecturer at Universidad Cardenal Herrera CEU (CEU Cardenal Herrera University, UCH-CEU) and biologist at "La Fe" Hospital in Valencia used massive sequencing techniques to identify new recurrent genes mutations ...

Dec 01, 2015
popularity2 comments 0

FDA approves tibsovo for acute myeloid leukemia

(HealthDay)—Tibsovo (ivosidenib) tablets have been approved by the U.S. Food and Drug Administration to treat relapsed or refractory acute myeloid leukemia (AML) among people with a defective IDH1 gene.

Jul 24, 2018
popularity0 comments 0

Acute myeloid leukemia (AML), also known as acute myelogenous leukemia, is a cancer of the myeloid line of blood cells, characterized by the rapid growth of abnormal white blood cells that accumulate in the bone marrow and interfere with the production of normal blood cells. AML is the most common acute leukemia affecting adults, and its incidence increases with age. Although AML is a relatively rare disease, accounting for approximately 1.2% of cancer deaths in the United States, its incidence is expected to increase as the population ages.

The symptoms of AML are caused by replacement of normal bone marrow with leukemic cells, which causes a drop in red blood cells, platelets, and normal white blood cells. These symptoms include fatigue, shortness of breath, easy bruising and bleeding, and increased risk of infection. Several risk factors and chromosomal abnormalities have been identified, but the specific cause is not clear. As an acute leukemia, AML progresses rapidly and is typically fatal within weeks or months if left untreated.

AML has several subtypes; treatment and prognosis varies among subtypes. Five-year survival varies from 15–70%, and relapse rate varies from 33-78%, depending on subtype. AML is treated initially with chemotherapy aimed at inducing a remission; patients may go on to receive additional chemotherapy or a hematopoietic stem cell transplant. Recent research into the genetics of AML has resulted in the availability of tests that can predict which drug or drugs may work best for a particular patient, as well as how long that patient is likely to survive.

This text uses material from Wikipedia licensed under CC BY-SA

Latest Spotlight News

Brain changes found in self-injuring teen girls

The brains of teenage girls who engage in serious forms of self-harm, including cutting, show features similar to those seen in adults with borderline personality disorder, a severe and hard-to-treat mental illness, a new ...